lyogenixlabs.com · research use only
Printed: 18/04/2026
For Research Use Only — Not for Human Consumption
This product is strictly intended for in-vitro research and laboratory use by qualified researchers. It is not approved for human or veterinary therapeutic use, self-administration, or any clinical application.
Retatrutide Injection Pen
Triple Incretin Agonist — Pre-Filled Pen
3 mL pre-formulated sterile solution — concentration specifications coming soon
Overview
The Retatrutide Injection Pen is a pre-filled, multi-dose injection pen device containing Retatrutide, the first-in-class triple GLP-1/GIP/Glucagon receptor agonist. This pen format provides a convenient delivery system for research protocols investigating the metabolic effects of simultaneous triple incretin pathway activation.
The pen device ensures precise dosing and consistent subcutaneous delivery, critical factors when studying the dose-dependent effects of this novel triple agonist. The pre-formulated solution eliminates reconstitution variables, improving reproducibility across research applications.
For detailed compound information, mechanism of action, and research applications, please refer to the Retatrutide lyophilized powder product page.
Chemical Profile
| Property | Details |
|---|---|
| Purity | ≥98% (HPLC verified) |
| Form | Pre-filled Injection Pen |
| Appearance | Clear to pale yellow sterile aqueous solution |
| Solubility | Pre-formulated sterile solution — no reconstitution required |
| Storage | 2°C – 8°C, protect from light |
Mechanism of Action
Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors. GLP-1R activation suppresses appetite and enhances insulin secretion. GIPR activation improves beta-cell function. Glucagon receptor activation promotes hepatic fatty acid oxidation and thermogenesis.
The pen delivery format provides consistent subcutaneous absorption kinetics, enabling reproducible pharmacokinetic profiles for research protocols. The pre-formulated solution maintains peptide stability and eliminates reconstitution-related variability.
For comprehensive mechanism details, see the Retatrutide lyophilized powder product page.
Research Applications
- Triple agonist dose-response research
- Pen device pharmacokinetics
- Metabolic research with standardized dosing
- Convenient multi-dose research protocols
Handling & Reconstitution
- 1Remove the pen from refrigerated storage and allow it to reach room temperature (15-25 minutes).
- 2Attach a new sterile pen needle according to device instructions.
- 3Prime the pen by dialing and expelling a small test dose.
- 4Dial the desired research dose.
- 5Administer subcutaneously per research protocol.
- 6Remove and safely dispose of the needle after each use.
- 7Return the pen to refrigerated storage (2°C – 8°C) immediately after use.
Product Specifications
- 1 × Pre-filled multi-dose injection pen (3 mL)
- Contains: Retatrutide in sterile solution
- Concentration: TBD — specifications coming soon
- Storage: 2°C – 8°C, protect from light
- Do not freeze
- Do not shake
Ingredients
Retatrutide, excipients
Certificate of Analysis
Full CoA with HPLC purity data and mass spectrometry confirmation is available for every batch.
Request CoARelated Products
Disclaimer
This product is intended for research and laboratory use only. Not for human consumption. LyoGenix Labs Pvt. Ltd. does not condone or promote the use of these compounds outside of legitimate research.
Authenticity Guarantee
Every LyoGenix product ships with a unique scratch code under a tamper-evident holographic label. Scratch the label to reveal your code and verify it here — confirming your product is genuine.
- Cryptographically unique code per box
- One-time verification — tracks first use
- Genuine LyoGenix Labs guarantee